Shares of Cardio Diagnostics Holdings surged 10.6% to $2.20 on August 20 as the micro-cap diagnostics firm filed an investor presentation ahead of a scheduled investor call, spotlighting its commercialization roadmap, AI-driven cardiovascular tests, and a key Medicare reimbursement milestone. For a company with a market capitalization hovering in single-digit millions, the question is whether the story matches the substance. Cardio Diagnostics' $854 Medicare Rate Looks Like a Breakthrough — But With Only $8,000 in Year-to-Date Revenue, Can the Math Ever Work?
Shares surged 10.6% to $2.20 as Cardio Diagnostics filed an investor presentation ahead of today's investor call, repackaging a commercialization narrative around AI-powered heart disease blood tests and a favorable Medicare payment rate. The pitch is polished, but the gap between the story and the financials remains enormous.
• Medicare Will Pay $854 Per Test, But Almost Nobody Is Ordering Tests Yet
CMS finalized a gapfill payment rate of $854 for the company's two clinical blood tests , a significant increase from preliminary rates of $350 and $684.76 . That's a meaningful per-unit price point — if orders materialize. But revenue remained nominal at just $5,400 for the most recent quarter and $8,000 year-to-date . Simple math: $8,000 in total revenue means roughly nine or ten tests have actually been billed across six months. An $854 rate means nothing without volume.
• Losses Dwarf Revenue by a Factor of Hundreds
The company reported a quarterly net loss of $1.5 million against that $5,400 in revenue . In Q1, the loss was $1.79 million on just $2,700 in revenue . Persistently negative operating cash flow and dependence on equity issuance — including net at-the-market stock sale proceeds of $18.75 million through mid-May — mean the company is funding itself by selling shares , diluting existing investors to stay afloat.
• The Company Has the Codes and the Lab, But Not the Customers
Cardio now has dedicated Medicare billing codes for both tests and the $854 rate took effect January 1, 2026 . It brought an in-house high-complexity lab online and began shipping reagents for an India rollout . Its go-to-market strategy has shifted toward non-reimbursement channels including telemedicine, concierge practices, employers, and unions — an implicit admission that insurance-covered adoption remains slow.
• The Investor Presentation Is the Catalyst, Not the Business Today's stock pop is driven by the narrative, not by new orders, partnerships, or revenue. The company's market capitalization sits near $5.3 million , and management itself has acknowledged that disclosure controls and procedures were not effective . At this scale, a single polished slide deck can move the stock — but investors should weigh the promotional machinery against a business that has generated roughly $8,000 in revenue across all of 2026. The reimbursement infrastructure is real; the commercial traction is not.